Parotid metastasis of nasopharyngeal carcinoma (NPC) is extremely rare. The current case report presents the history of a 41-year old male with the primary symptom of a right parotid gland mass who was diagnosed with NPC by histopathology in 2006 and was staged as having cT 3 N 2 M 0 disease (stage III, American Joint Committee on Cancer staging system, 2002). Histopatho logical examination of a partial excision of the mass on the right parotid and the neoplasm in the pharynx nasalis revealed poorly differentiated squamous cell carcinoma. The patient received radiotherapy and concurrent chemotherapy. Grade 2 skin reaction, grade 2 oropharyngeal mucositis and grade 3 xerostomia were detected during treatment. The patient achieved a complete clinical response by 1 month after treatment. At the last follow-up in August 2009, the patient was in a good condition and living a normal life. The primary symptom of parotid gland mass in patients with NPC is commonly misdiagnosed and a pathological analysis can be considered a reliable method for confirming diagnosis.
Introduction
Nasopharyngeal carcinoma (NPC) is one of the most common epithelial malignancies of the head and neck occurring worldwide, 1, 2 and lymphoid metastases are found in almost 90% of patients at diagnosis. 3 -6 Radiotherapy is the most efficacious therapeutic approach, 7 while chemotherapy is also needed in advanced disease. 8 Histologically, the nasopharyngeal stroma is rich in lymphatic plexus and lymphoid tissue that often includes reactive lymphoid follicles, and the epithelium is commonly infiltrated by many small lymphoid cells. Carcinoma originating from one side of the nasopharynx may occur on the other side via lymph node metastases. There are, however, few cases of parotid lymph node metastases. 9 -11 The present report describes a case of parotid lymph node metastases of NPC. The authors also review the international literature with reference to this rare metastatic site.
Case report
In October 2006, a 41-year old male was admitted to the Cancer Centre of the Union Parotid gland metastasis of nasopharyngeal carcinoma Hospital, Wuhan, China, with an 8-month history of a progressively enlarging mass in the right pre-auricular area that had undergone a recent, rapid increase in size and was accompanied by an absence of symptoms. During examination, a hard tumour was palpable, which was fixed to the underlying soft tissues in the right parotid gland and measured about 7 × 6 × 6 cm with a defined boundary. Two tender and unfixed lymph nodes measuring 0.7 × 0.5 × 0.5 cm could be palpated in levels II and V of the right cervicum. The skin of the cervical region was normal in appearance and no lesions were found in the oral cavity. No facial nerve palsy was present. During the course of the disease, there had been no symptoms of headache, diplopia, abnormal deglutition, nasal occlusion or blood-stained nasal discharge. The patient underwent a partial excision and biopsy of the mass, and histopathological examination of a tissue sample proved it to be metastatic nonkeratinizing squamous cell carcinoma. Immunohistochemical expression of pan cytokeratin and cytokeratin 5/6 were positive (Figs 1 and 2), whilst expression of α-smooth muscle actin, S-100 and leucocyte common antigen were negative (data not shown).
The usual pre-operative work-up was implemented. Magnetic resonance imaging of the nasopharynx and neck region demonstrated a mass in the nasopharynx cavity that involved the clivus and right parotid gland. Pharyngorhinoscopy showed a neoplasm in the pharynx nasalis, while biopsy revealed poorly differentiated squamous cell carcinoma. Chest computed tomography (CT) and bone emission CT were normal. Laboratory studies, which included full blood cell count, electrolytes, urinalysis and liver function tests, all had results within normal limits. The final diagnosis for this patient was nasopharyngeal carcinoma cT 3 N 2 M 0 , using the 2002 American Joint Committee on Cancer (AJCC) staging system. 12 The patient was treated with CT-based three-dimensional radiotherapy. The target volume, encompassing the primary tumour and the draining anterior neck nodes, received 2.0 Gy/fraction at a rate of five fractions per week. The total dose for the pharynx nasalis was 70 Gy in 35 fractions 
Discussion
Nasopharyngeal carcinoma is one of the most common cancers of the head and neck, and lymphoma metastases occur in almost 90% of patients at diagnosis. Superior deep cervical lymph nodes are most frequently involved, with spread reaching the supraclavicular region.
Occasionally, jumping metastases are detected. In a study by Ng et al., 13 the incidence of level II, III and IV cervical lymph node metastases was 95.5%, 60.7% and 34.8%, respectively, but the incidence of parotid lymph node metastases was very low in all cases. During the process of diagnosis, only 1.4% -3.4% cases of parotid lymph node metastases could be detected, along with metastasis of the ipsilateral cervical lymph nodes.
The parotid nodes are divided into four subgroups: 14, 15 (i) subcutaneous preauricular nodes; (ii) superficial intra-parotid nodes; (iii) deep intra-parotid nodes; and (iv) sub-parotid nodes. The most superficial group, the subcutaneous pre-auricular nodes, are located in front of the tragus and drain lymph from the frontal skin, eyelids and conjunctiva into the intra-parotid The deep intraparotid nodes are located throughout the parotid gland tissue, mainly occurring along the external carotid artery and the intraparotid part of the external jugular vein. 15 Some intra-glandular parotid nodes are connected to the sub-parotid nodes. The sub-parotid nodes are close to the internal jugular vein and internal carotid artery, and collect afferent lymphatic vessels from the nasal cavity, nasopharynx and eustachian tube. The sub-parotid nodes also have links with the retropharyngeal nodes and, therefore, share caudal drainage of the intra-parotid nodes into the superior deep cervical lymph nodes. In nasopharyngeal carcinoma, there are three ways in which cancer can metastasize to the parotid gland lymph nodes: (i) via lateral retropharyngeal lymph nodes to the parotid gland tissue; (ii) via superior deep cervical lymph nodes; and (iii) via parotid gland tissue involvement. Cancer can also invade the parotid gland tissue directly by way of the peripharyngeal space.
In conventional radiation therapy for nasopharyngeal carcinoma, 100% of the volume of the parotid gland is included in the field and the dose normally reaches 60 -70 Gy. As a result, the function of the parotid gland becomes badly impaired, salivary secretion decreases and xerostomia occurs which, in consequence, seriously impairs quality of life. 16, 17 In intensity-modulated radiation therapy (IMRT), the high-dose region is highly conformed to the nasopharyngeal carcinoma target in three dimensions and the dose for the nasopharyngeal carcinoma target increases whilst the dose and volume within the field of the parotid gland tissue decreases. As a result, the risk of complications related to radiotherapy is reduced and the ratio of gains elevated. 18 Consequently, IMRT is a leading method of treatment, especially for head and neck cancer.
In IMRT for the treatment of head and neck cancer, where the parotid gland has not been invaded, we usually restrict the dose to no greater than 25 Gy for 50% by volume of the parotid gland. Some reports have, however, noted metastasis of the parotid peripheral nodes occurring after IMRT treatment in patients with nasopharyngeal carcinoma and other head and neck cancers. 19, 20 For example, Cannon and Lee 19 reported three cases of head and neck cancer where relapse was observed in the superficial part of the parotid gland after IMRT treatment. Two cases had multiple enlarged lymph nodes on both sides of the cervix before treatment and enlarged cervical lymph nodes in region II on 20 At follow-up, three of the cases were detected to have relapse in the superficial part of the parotid gland and, of these, two had an invaded carotid sheath and retropharyngeal lymph nodes metastasis on both sides prior to treatment, and one of these cases also had multiple enlarged cervical lymph nodes on both sides. The third case had an enormous upper cervical lymph node on the ipsilateral side.
Consequently, in cases with retropharyngeal lymph node metastasis and enormous cervical lymph nodes, especially in region II, the parotid gland should be sufficiently included in the field of radiotherapy in order to decrease relapse and metastasis. For patients who have a positron emission tomography examination, if the image shows unspecific lymph nodes but no signals of hypermetabolism in the parotid gland region, along with multiple enlarged cervical lymph nodes or level II lymph node involvement, metastasis should be suspected and the parotid gland should be included in the target volume. The case of parotid lymph node metastases of NPC described in the present report remained well in follow-up examinations with neither relapse nor metastasis.
